Targeted Therapy
Approved for: NSCLC
Biomarker: NTRK

Larotrectinib (Vitrakvi) is a FDA-approved treatment for non-small cell lung cancer (NSCLC) with neurotrophic receptor tyrosine kinase (NTRK) gene fusion.

Related Research News

Pre- and Post-surgical Immunotherapy-based Treatment Significantly Improved Lung Cancer Outcomes

Pre- and Post-surgical Immunotherapy-based Treatment Significantly Improved Lung Cancer Outcomes

Long-term study reveals ‘ever-changing’ nature of lung cancer

Long-term study reveals ‘ever-changing’ nature of lung cancer

Lung Cancer Trial Has Broader Eligibility Criteria, Overcomes Barriers

Lung Cancer Trial Has Broader Eligibility Criteria, Overcomes Barriers